A class of glucagon-like peptide-1 receptor agonists or GLP-1 RAs (Rybelsus, Wegovy, Ozempic and Mounjaro, their generic names semaglutide and tirzepatide) have, in a remarkably short time, become a major topic of conversation in India. They are now discussed in gyms, beauty salons, office corridors, wedding-preparation groups, among celebrities, and across countless social-media channels.

Marketed as serious solutions for weight loss, these medicines have acquired an aura of glamour. There is more discussion, more fascination, and unfortunately, more misuse. Yet behind this enthusiasm lies a troubling reality: public understanding is often superficial, incomplete, misguided, or simply wrong.

Mistaken Beliefs and Realities

A common early misconception is that all individuals with obesit

See Full Page